Dr. Gabriele...
Transcript of Dr. Gabriele...
![Page 1: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/1.jpg)
Ist die Zulassung das einzige Ziel? Eine Übersicht über aktuelle
Entwicklungen in Pharma DiagnostikEntwicklungen in Pharma, Diagnostik und Medizintechnik
Dr. Gabriele Dallmann
VBU-Mitgliederversammlungg g
4. Dezember 2012
![Page 2: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/2.jpg)
Dr Gabriele Schäffner-Dallmann Focus: BiopharmaceuticalsDr. Gabriele Schäffner-Dallmann. Focus: Biopharmaceuticals
Spezialist für Entwicklung und Zulassung von Biopharmazeutika inkl. ATMPs und Biosimilars
Ex-Regulator PEI: Verantwortlichkeit für Zulassung und
Chargenprüfung aller Antikörper-haltigen A i itt lArzneimittel
EMA: Mitglied in Zulassungs-Gremien und E perten Gr ppenExperten-Gruppen
Entwicklung Regularien und Verfahren B t Beratung Training (EUCRAF)
2
![Page 3: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/3.jpg)
Medicinal Products Medical DevicesDrugs
(Chemical entities)
Biopharmaceuticals(Chemical entities)
AIMD MD IVD
VaccinesCells
Tissuesrec.
ProteinsBlood
Products
Combination Product ? 3
![Page 4: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/4.jpg)
In jedem Fall:In jedem Fall:Einordnung des Produktes gemäß Definition derEinordnung des Produktes gemäß Definition der
Richtlinien bzw Verordnungen Arzneimittel? Medizinprodukt?Medizinprodukt?
Verfahren Zulassung oder Zertifizierung oder Überwachung?
BehördeBehörde Nationale Zulassungsbehörde oder EMA? Notified Body?
Üb h b hö d ? Überwachungsbehörde?4
![Page 5: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/5.jpg)
No “Combination Product” Regulatory Status in Europe medicinal product or medical device definitions
Regulatory status defined by primary mode of action (PMOA):(PMOA):
- Metabolic, pharmacological, immunological Medicinal Product MPD
- Other and in particular mechanical/physical p p yMedical Device MDD/AIMDD/IVD
5
![Page 6: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/6.jpg)
The current Pharma dilemma Assuming a TOP20 Company with 8 new targets, all for
autoimmune diseases such as RA, psoriasis, Crohn‘s disease E h t t i t l l i th l diff ti t Each target unique, central role in pathology, differentiates
patients from healthy subjects, promising based on postulated MoA (Mode of Action)MoA (Mode of Action)
Clinical trial designs take the currently approved products as basisbasis
The dilemma: Physicians do not support them: „we do not see these patients anymorePhysicians do not support them: „we do not see these patients anymore
in our practice“ Clinical trials in other regions suffer from high placebo effects and low
f l i t i it tsuccessful screening rates in recruitment Pricing: HTA agencies are national and require additional benefit
Consequence: the definition “the market” has changed! Consequence: the definition the market has changed! 6
![Page 7: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/7.jpg)
Biological/biotech products BiologicalsNaturally sourced products
Recombinant proteinsrDNA technologyNaturally sourced products
Hormones
rDNA technologyMonoclonal antibodies
Blood products (IVIG, albumin, clotting factors)
ErythropoeitinGrowth hormoneFilgrastimRecombinant hormones
ATMPsGene Therapy Recombinant hormones
Recombinant enzymesGene TherapySomatic Cell Therapy
Recombinant vaccinesFusion proteins
Tissue Engineered Products
7
![Page 8: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/8.jpg)
EU / EEAEU / EEA
Austria (AU) Belgium (BE) Bulgaria (BG) Cyprus (CY) Czech Republic (CZ)
Denmark (DK) Estonia (EE) Finland (FI) France (FR) Germany (DE) Greece (EL)National agencies
Hungary (HU) Ireland (IE) Italy (IT) Latvia (LV) Lithuania (LT)
Luxembourg (LU) Malta (MT) Netherlands (NL) Poland (PL) Portugal (PT) Romania (RO)
Slovakia (SK) Slovenia (SI) Spain (ES) Sweden (SE) United Kingdom (UK)
+EEA (Iceland, Norway, Liechtenstein)
EMA8
EMA
![Page 9: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/9.jpg)
PhPharma
SCIENTIFIC ADVICE Regulatory procedures
CLINICAL TRIAL AUTHORISATION
MARKETING AUTHORISATION
Regulatory procedures
Agencies involvedMARKETING AUTHORISATION
9
![Page 10: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/10.jpg)
AGENCIES INVOLVED
• 31 national agencies and EMAg
SCIENTIFIC ADVICE
N ti ll d t ll (EMA)• Nationally and centrally (EMA)
CLINICAL TRIAL AUTHORISATION
• Nationally but register of clinical trials at EMA
MARKETING AUTHORISATIONMARKETING AUTHORISATION
• Centralised and rarely national (DCP and MRP) procedure
• Experts of national agencies perform the scientific assessment
• EMA as the central administration for the centralised procedure
10
p
![Page 11: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/11.jpg)
Clinical Trials in EU
Ph IPhase I Phase I/IIa Phase IIb Phase III
• AutoimmunePhase I• 1 Phase I
Unit• HV
• 1 Univers. hospital
• Pat. withAuto-immune
• 3 Univers. Hospitals, Tumour patients
• Dosis-Finding• PoC
• Autoimmune disease
prov
al
disease
App
UKDE 12 countries in EU,UK
SE NL, PL, Ukraine
12 countries in EU,Except UK,SwitzerlandUSA
EMAUkraine
11
![Page 12: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/12.jpg)
CTA: relevant guidanceCTA: relevant guidancehttp://ec.europa.eu/health/documents/eudralex/vol-10/
EU Commission
12
![Page 13: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/13.jpg)
MARKETING AUTHORISATION IN EU
1. Centralised Procedure (CP)2. Decentralised Procedure (DCP)3 Mutual Recognition Procedure (MRP)3. Mutual Recognition Procedure (MRP)
13
![Page 14: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/14.jpg)
Is there a choice for biopharmaceuticals?BiologicalsNaturally sourced products
Recombinant proteinsrDNA technologyNaturally sourced products
Hormones
rDNA technologyMonoclonal antibodies
Blood products (IVIG, albumin, clotting factors)
ErythropoeitinGrowth hormoneFilgrastimRecombinant hormones
ATMPsGene Therapy Recombinant hormones
Recombinant enzymesGene TherapySomatic Cell Therapy
Recombinant vaccinesFusion proteins
Tissue Engineered Products
14
![Page 15: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/15.jpg)
Is there a choice for biopharmaceuticals?Is there a choice for biopharmaceuticals?
• Not really• Mainly centralised procedure!• Mainly centralised procedure!• MRP for existing marketing authorisations – all
those for which the centralised procedure is not applicablenot applicable
• DCP only for those which are not eligible for th CPthe CP
15
![Page 16: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/16.jpg)
Agency of the European Union based in Canary Wharf,The EMA
g y p y ,London
Responsible for the administrative and proceduralaspects of EU regulations and directives related to theaspects of EU regulations and directives related to theevaluation and safety monitoring of medicines in the EU
Executive Director and secretariat of ca 550 full-timestaff
Reports to the Pharmaceuticals Unit of the DG Healthand Consumers in the EU Commission (DG SANCO)and Consumers in the EU Commission (DG SANCO)
Independent Management Board responsible forbudgetary and planning matters, monitoring of theAgency’s performance and appointment of theExecutive Director
With the exception of the pediatric activities no scientific
Link to EMA website:
With the exception of the pediatric activities, no scientificassessment and responsibility
16
Link to EMA website:http://www.ema.europa.eu/ema/index.jsp?curl=/pages/home/Home_Page.jsp
![Page 17: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/17.jpg)
17
![Page 18: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/18.jpg)
EMA responsibility: the mandatory scope of the centralised procedure
(Regulation 726/2004)
18
![Page 19: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/19.jpg)
Centralised Procedure mandatory for
– Biotech products – ATMPsATMPs– New active substances for treatment of:
• AIDSAIDS• Cancer• Neurodegenerative disorders
Di b t• Diabetes• Auto-immune diseases/immune dysfunction• Viral diseases
– Orphan drugs
19
![Page 20: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/20.jpg)
Centralised Procedure optional forCentralised Procedure optional for
– New active substances (outside mandatoryNew active substances (outside mandatory scope indications)P d t ff i i ifi t th ti– Products offering significant therapeutic, scientific or technical innovation
– Products in the interest of patients at Community levelCommunity level
– Generics of products authorised through the Centralised procedure
20
![Page 21: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/21.jpg)
Centralised Procedure – Key Points
• 1 Marketing Authorisation valid throughout the EU / EEA• 1 Trademark• 1 Legal status• Application submitted to one agency only: EMApp g y y• Review process includes all Member States• It is not possible to withdraw the application from selectedIt is not possible to withdraw the application from selected
Member States during the procedure• Results in a pan-European Decision (positive or negative)Results in a pan European Decision (positive or negative)• Expensive (254,100 Euro basic fee = 1 strength associated with
1 pharmaceutical form)1 pharmaceutical form)• Complex logistics and time-lines (submission to approval
14-15 months plus preparation period of 9 months)21
14 15 months plus preparation period of 9 months)
![Page 22: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/22.jpg)
N di i l d t li ti t thNew medicinal product applications at theEMA via the CP
92
Biologicals SM
79
49
2315
10
2009 2010 201120% failed 30% / 10% failed26% / 23% failed20% failed 30% / 10% failed26% / 23% failed
2011: 90 reviewsBiologicals: 10 (11%), 7 positive (70%)SM: 48 (53%) 41 positive (85%)
22
SM: 48 (53%), 41 positive (85%) Generics: 31 (34%), 30 positive (97%)SM + Generics: 79 (88%), 71 positive (90%)
![Page 23: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/23.jpg)
Success RateSuccess Rate
Biopharmaceuticals: Success rate 66-80%Biopharmaceuticals: Success rate 66-80%
Small Molecules: Success rate 80-88%
Main reason for failure for all: clinical dataMain reason for failure for all: clinical data insufficient adherence to regulatory principles in
the clinical development insufficient or irrelevant clinical effect or insufficient or irrelevant clinical effect or
unfavourable safety
23
![Page 24: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/24.jpg)
Authorized and rejected biosimilarsj1 Omnitrope (somatropin) Sandoz Authorised
2 Valtropin (somatropin) Biopartners Authorised
3 Alpheon (IFN alfa-2a) Biopartners Negative
4 Biferonex (IFN beta-1a) Biopartners Negative
5 Binocrit (Epo alfa) Sandoz( )Authorised6 Epoetin alfa Hexal (epo alfa) Hexal
7 Abseamed (epo alfa) Medice
8 Silapo (epo zeta) Stada8 Silapo (epo zeta) StadaAuthorised9 Retacrit (epo zeta) Hospira
10 Epostim (epoetin alfa) ood cell production Reliance GeneMedix Plc Withdrawn
11 I li M l Sh t (h i li ) M l Lif S i‘ Withd (2 )11 Insulin Marvel Short (human insulin) Marvel Lifes Sci‘ Withdrawn (2x)
12 Insulin Marvel Intermediate (human insulin) Marvel Life Sci‘ Withdrawn (2x)
13 Insulin Marvel Long (human insulin) Marvel Life Sci‘ Withdrawn (2x)
14 Filgrastim Ratiopharm (filgrastim) Ratiopharm
Authorised15 Ratiograstim (filgrastim) Ratiopharm
16 Biograstim (filgrastim) CT Arzneimittel GmbH
17 Tevagrastim (filgrastim) Teva
18 Filgrastim Hexal (filgrastim) HexalAuthorised19 Zarzio (filgrastim) Sandoz19 Zarzio (filgrastim) Sandoz
20 Nivestim (filgrastim) Hospira Authorised24
![Page 25: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/25.jpg)
Some players in the field of biosimilar tib diantibodies
Amgen-Watson-PRAAmgen Watson PRA Boehringer Ingelheim
Celltrion Hospira first infliximab under review in EU Celltrion-Hospira first infliximab under review in EU Coherus -Daiichi Sankyo
Merck Hanwha Parexel Merck-Hanwha-Parexel Merck Serono – Dr. Reddys
M l Bi Mylan-Biocon Pfizer
S Bi Q i il Samsung-Biogen-Quintiles Sandoz TEVA
25
![Page 26: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/26.jpg)
26
![Page 27: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/27.jpg)
27
![Page 28: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/28.jpg)
SCIENTIFIC ADVICE IN EUSCIENTIFIC ADVICE IN EU
Regulatory input by agencies regarding Development plan
• e.g. choice of study population, endpoints, statistical plan Submission strategy Risk management
Two routes in Europe National Scientific Advice CHMP Scientific Advice at EMA
Considerations on the scope of the scientific advice: Preparation of the FTIM study,
f / ?
National agencyof the country of
i.e. mainly pre-clinical programme and manufacture/control? Discussion of critical issues related
to the manufacture characterisation
ythe first CTA
Both, national agency of theto the manufacture, characterisation
and testing scheme? Discussion of the whole
agency of thecountry of the firstCTA or EMA
28
clinical development plan? EMA
![Page 29: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/29.jpg)
Medizinprodukte National geregelt - heterogene Behördenlandschaft Richtlinien:
Richtlinie 90/385/EWG über aktive implantierbare Medizinprodukte (AIMD)
Richtlinie 93/42/EWG über Medizinprodukte (MDD) Richtlinie 98/79/EG über In-vitro-Diagnostika (IVDD)
Eigenverantwortlichkeit der Hersteller Anmeldung bei der Behördeg Einordnung des Produktes gemäß Definition, dann in der Regel
Selbstzertifizierung für CE mark („self-declaration of conformity”) Haupt-Komponenten: Qualitäts-Sicherungs-System, technische
Dokumentation und Nachverfolgungs-System nach Herstellung
29
![Page 30: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/30.jpg)
IVD-Einordnung Jedes Medizinprodukt, das als Reagenz, Reagenzprodukt,
Kalibriermaterial, Kontrollmaterial, Kit, Instrument, Apparat, G ät d S t i l d i V bi d it i dGerät oder System - einzeln oder in Verbindung miteinander -nach der vom Hersteller festgelegten Zweckbestimmung zur In-vitro-Untersuchung von aus dem menschlichen Körpervitro-Untersuchung von aus dem menschlichen Körper stammenden Proben, einschließlich Blut- und Gewebespenden, verwendet wird und ausschließlich oder hauptsächlich dazu pdient, Informationen zu liefern über physiologische oder pathologische Zustände oderp y g p g über angeborene Anomalien oder zur Prüfung auf Unbedenklichkeit und Verträglichkeit bei den g g
potentiellen Empfängern oder zur Überwachung therapeutischer Maßnahmen.g p
30
![Page 31: Dr. Gabriele Dallmannv-b-u.org/vbu_media/Downloads/Mitgliederversammlung2012/121204+VBU+…Biopharmazeutika inkl. ATMPs und Biosimilars Ex-Regulator PEI: Verantwortlichkeit für Zulassung](https://reader030.fdocument.pub/reader030/viewer/2022040315/5e19de3bf7866b1572241c37/html5/thumbnails/31.jpg)
Vielen Dank!